STAR-EV: Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer (clinicaltrials.gov) - Sep 18, 2026 - P1/2 | N=19 | Recruiting | Sponsor: University of Texas Southwestern Medical Center | Trial completion date: Jul 2027 ➔ Sep 2029 | Trial primary completion date: Jul 2026 ➔ Sep 2028
Trial completion date • Trial primary completion date • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor
|